XEN D0103

Drug Profile

XEN D0103

Alternative Names: S 066913; XEN-D0103

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xention
  • Developer Servier; Xention
  • Class Antiarrhythmics
  • Mechanism of Action Kv1.5 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atrial fibrillation

Most Recent Events

  • 14 May 2015 Xention completes a phase II clinical trial in Atrial fibrillation in United Kingdom (EudraCT2013-004456-38)
  • 12 Nov 2014 Phase-II clinical trials in Atrial fibrillation in Poland (PO) (EudraCT2014-002333-63)
  • 11 Apr 2014 Phase-II clinical trials in Atrial fibrillation in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top